Where is Diploid located?

Diploid is headquartered in Leuven, Belgium.

How many employees does Diploid have?

As of Jun 30, 2026, the latest employee count at Diploid is 6.

Is Diploid a funded company?

Diploid is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Diploid rank among its competitors?

Diploid ranks 124th amongst 634 active competitors, of which 109 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Twin Strand Bio, which secured $5.66M in Feb, 2025.

Who are the top competitors of Diploid?

Diploid's top competitors include Foundation Medicine, DNAnexus and Fabric Genomics. Among them, Twin Strand Bio secured the most recent funding round in February, 2025.

Diploid - 2026 Company Profile, Team & Competitors

Q: Is Diploid an acquired company?

Diploid got acquired by Invitae on Mar 10, 2020.

Diploid is an acquired company based in Leuven (Belgium), founded in 2014 by Peter Schols. It operates as a Provider of software to diagnose rare diseases. The company has 634 active competitors, including 109 funded and 62 that have exited. Its top competitors include companies like Foundation Medicine, DNAnexus and Fabric Genomics.

Company Details

Provider of software to diagnose rare diseases. The company uses a proprietary machine-learning algorithm to analyze patient data generated by next-gen sequencing technologies. In addition, Diploid also runs GentleLabs, a direct-to-consumer testing company that tests saliva samples for over 1700 genetic disorders and mails the results to the customer's physicians.

Website: diploid.com
Social

Key Metrics

Founded Year

2014

Location

Leuven, Belgium

Stage

Acquired

Ranked

124^th among 634 active competitors

Employee Count

6 as on Jun 30, 2026

Similar Companies

Foundation Medicine & 860 more

Exit Details

Acquired by Invitae (Mar 10, 2020)

View Diploid's full profile

Diploid got acquired by Invitae on Mar 10, 2020 at an acquisition amount of $*****.

Click here to take a look at Diploid's acquisition in detail

Diploid has not raised any funding rounds yet.

The founders of Diploid is Peter Schols.

Here are the details of Diploid's key team members:

Peter Schols: Founder & CEO of Diploid.

View details of Diploid's Founder profiles and Board Members

Diploid's employee count trend

Diploid has 6 employees as of Jun 26. Here is Diploid's employee count trend over the years:

Uncover Diploid's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Diploid include Foundation Medicine, DNAnexus and Fabric Genomics. Here is the list of Top 10 competitors of Diploid, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Google Ventures & 11 others	71/100
2nd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
3rd	Fabric Genomics 2009, Oakland (United States), Acquired	AI-based disease diagnosis and genomic analysis tool for providers	$32.8M	Artis Ventures, LDV Partners & 12 others	67/100
4th	Burning Rock 2014, Guangzhou (China), Public	Developer of personalised diagnostic and treatment services based on genomic big data analysis	$203M	LYFE Capital, Legend Star & 7 others	65/100
5th	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	65/100
6th	Twin Strand Bio 2015, Seattle (United States), Series B	Developer of DNA sequencing technology to identify genomic mutations	$84M	S32, Madrona & 9 others	65/100
7th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	Khosla Ventures, SoftBank Vision Fund & 16 others	63/100
8th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, Nextech Invest & 10 others	63/100
9th	Lantern Pharma 2013, Dallas (United States), Public	Developing drug and companion diagnostics for multi-drug resistant cancers	$7.12M	Green Park & Golf Ventures, Bios Partners ... & 3 others	62/100
10th	Personal Genome 2010, Baltimore (United States), Acquired	Provider of advanced technology solutions for cancer genome analysis	$327M	New Enterprise Associates, Camden Partners ... & 17 others	60/100
124th	Diploid 2014, Leuven (Belgium), Acquired	Provider of software to diagnose rare diseases	-	-	33/100